The association of renin-angiotensin system blockade use with the risks of cognitive impairment of aging and Alzheimer's disease: A meta-analysis

Journal of Clinical Neuroscience

Volumn 33, Issue , 2016, Pages 32-38

  Zhuang, Shan ^a,b   Wang, Hai Feng ^b   Wang, Xin ^b   Li, Jun ^b   Xing, Cheng Ming ^b  

^a Department of Neurosurgery   (China)

^b QINGDAO UNIVERSITY   (China)

Author keywords

Alzheimer disease; Angiotensin receptor blocker; Angiotensin converting enzyme inhibitor; Cognitive impairment of aging; Meta analysis; Renin angiotensin system

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR;

AGING; ALZHEIMER DISEASE; COGNITIVE DEFECT; DISEASE ASSOCIATION; DRUG EFFICACY; HUMAN; NEUROPROTECTION; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; RISK ASSESSMENT; RISK REDUCTION; COGNITIVE DYSFUNCTION; COMPLICATION; DRUG EFFECTS; META ANALYSIS;

AGING; ALZHEIMER DISEASE; ANGIOTENSIN RECEPTOR ANTAGONISTS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; COGNITIVE DYSFUNCTION; HUMANS; RENIN-ANGIOTENSIN SYSTEM;

EID: 84992365494     PISSN: 09675868     EISSN: 15322653     Source Type: Journal    
DOI: 10.1016/j.jocn.2016.02.036     Document Type: Review

References (50)

1. [1] Sloane, P.D., Zimmerman, S., Suchindran, C., et al. The public health impact of Alzheimer's disease, 2000–2050: potential implication of treatment advances. Annu Rev Public Health 23 (2002), 213–231.
2. [2] Behl, C., Brain aging and late-onset Alzheimer's disease: many open questions. Int Psychogeriatr 24 (2012), S3–S9.
3. [3] Bondareff, W., Age-related changes in brain extracellular space affect processing of amyloid-beta peptides in Alzheimer's disease. J Alzheimer's Dis 35 (2013), 1–6.
4. [4] Chang-Quan, H., Hui, W., Chao-Min, W., et al. The association of antihypertensive medication use with risk of cognitive decline and dementia: a meta-analysis of longitudinal studies. Int J Clin Pract 65 (2011), 1295–1305.
5. [5] Johnson, M.L., Parikh, N., Kunik, M.E., et al. Antihypertensive drug use and the risk of dementia in patients with diabetes mellitus. Alzheimer's Dement 8 (2012), 437–444.
6. [6] Hanon, O., Seux, M.L., Lenoir, H., et al. Prevention of dementia and cerebroprotection with antihypertensive drugs. Curr Hypertens Rep 6 (2004), 201–207.
7. [7] Peila, R., White, L.R., Masaki, K., et al. Reducing the risk of dementia: efficacy of long-term treatment of hypertension. Stroke 37 (2006), 1165–1170.
8. [8] Fournier, A., Oprisiu-Fournier, R., Serot, J.M., et al. Prevention of dementia by antihypertensive drugs: how AT1-receptor-blockers and dihydropyridines better prevent dementia in hypertensive patients than thiazides and ACE-inhibitors. Expert Rev Neurother 9 (2009), 1413–1431.
9. [9] Shah, K., Qureshi, S.U., Johnson, M., et al. Does use of antihypertensive drugs affect the incidence or progression of dementia? A systematic review. Am J Geriatr Pharmacother 7 (2009), 250–261.
10. [10] Hajjar, I., Hart, M., Milberg, W., et al. The rationale and design of the antihypertensives and vascular, endothelial, and cognitive function (AVEC) trial in elderly hypertensives with early cognitive impairment: role of the renin angiotensin system inhibition. BMC Geriatr, 9, 2009, 48.
11. [11] Weber, M.A., Interrupting the renin-angiotensin system: the role of angiotensin-converting enzyme inhibitors and angiotensin II receptor antagonists in the treatment of hypertension. Am J Hypertens 12 (1999), 189S–194S.
12. [12] Lee, J., Chai, S.Y., Mendelsohn, F.A., et al. Potentiation of cholinergic transmission in the rat hippocampus by angiotensin IV and LVV-hemorphin-7. Neuropharmacology 40 (2001), 618–623.
13. [13] Tota, S., Hanif, K., Kamat, P.K., et al. Role of central angiotensin receptors in scopolamine-induced impairment in memory, cerebral blood flow, and cholinergic function. Psychopharmacology 222 (2012), 185–202.
14. [14] Marchesi, V.T., Alzheimer's dementia begins as a disease of small blood vessels, damaged by oxidative-induced inflammation and dysregulated amyloid metabolism: implications for early detection and therapy. FASEB J 25 (2011), 5–13.
15. [15] Hajjar, I., Rodgers, K., Do angiotensin receptor blockers prevent Alzheimer's disease?. Curr Opin Cardiol 28 (2013), 417–425.
16. [16] Zou, K., Yamaguchi, H., Akatsu, H., et al. Angiotensin-converting enzyme converts amyloid beta-protein 1–42 (Abeta(1–42)) to Abeta(1–40), and its inhibition enhances brain Abeta deposition. J Neurosci 27 (2007), 8628–8635.
17. [17] Zou, K., Michikawa, M., Angiotensin-converting enzyme as a potential target for treatment of Alzheimer's disease: inhibition or activation?. Rev Neurosci 19 (2008), 203–212.
18. [18] Hu, J., Igarashi, A., Kamata, M., et al. Angiotensin-converting enzyme degrades Alzheimer amyloid beta-peptide (A beta); retards A beta aggregation, deposition, fibril formation; and inhibits cytotoxicity. J Biol Chem 276 (2001), 47863–47868.
19. [19] Kehoe, P.G., Passmore, P.A., The renin-angiotensin system and antihypertensive drugs in Alzheimer's Disease: current standing of the angiotensin hypothesis?. J Alzheimer's Dis, 2012, S251–S268.
20. [20] Sink, K.M., Leng, X., Williamson, J., et al. Angiotensin-converting enzyme inhibitors and cognitive decline in older adults with hypertension: results from the Cardiovascular Health Study. Arch Intern Med 169 (2009), 1195–1202.
21. [21] Levi Marpillat, N., Macquin-Mavier, I., Tropeano, A.I., et al. Antihypertensive classes, cognitive decline and incidence of dementia: a network meta-analysis. J Hypertens 31 (2013), 1073–1082.
22. [22] Ohrui, T., Matsui, T., Yamaya, M., et al. Angiotensin-converting enzyme inhibitors and incidence of Alzheimer's disease in Japan. J Am Geriatr Soc 52 (2004), 649–650.
23. [23] Ye, R., Hu, Y., Yao, A., et al. Impact of renin-angiotensin system-targeting antihypertensive drugs on treatment of Alzheimer's disease: a meta-analysis. Int J Clin Pract, 2015.
24. [24] Hajjar, I., Catoe, H., Sixta, S., et al. Cross-sectional and longitudinal association between antihypertensive medications and cognitive impairment in an elderly population. J Gerontol Series A, Biol Sci Med Sci 60 (2005), 67–73.
25. [25] Higgins, J.P., Altman, D.G., Gotzsche, P.C., et al. The Cochrane Collaboration's tool for assessing risk of bias in randomised trials. BMJ, 343, 2011, d5928.
26. [26] DerSimonian, R., Laird, N., Meta-analysis in clinical trials. Control Clin Trials 7 (1986), 177–188.
27. [27] Higgins, J.P., Thompson, S.G., Quantifying heterogeneity in a meta-analysis. Stat Med 21 (2002), 1539–1558.
28. [28] Altman, D.G., Bland, J.M., Interaction revisited: the difference between two estimates. BMJ, 326, 2003, 219.
29. [29] Yasar, S., Xia, J., Yao, W., et al. Antihypertensive drugs decrease risk of Alzheimer disease: Ginkgo Evaluation of Memory Study. Neurology 81 (2013), 896–903.
30. [30] Khachaturian, A.S., Zandi, P.P., Lyketsos, C.G., et al. Antihypertensive medication use and incident Alzheimer disease: the Cache County Study. Arch Neurol 63 (2006), 686–692.
31. [31] Li, N.C., Lee, A., Whitmer, R.A., et al. Use of angiotensin receptor blockers and risk of dementia in a predominantly male population: prospective cohort analysis. BMJ, 340, 2010, b5465.
32. [32] Qiu, W.Q., Mwamburi, M., Besser, L.M., et al. Angiotensin converting enzyme inhibitors and the reduced risk of Alzheimer's disease in the absence of apolipoprotein E4 allele. J Alzheimer's Dis 37 (2013), 421–428.
33. [33] Hsu, C.-Y., Huang, C.-C., Chan, W.-L., et al. Angiotensin-receptor blockers and risk of Alzheimer's disease in hypertension population. Circ J 77 (2013), 405–410.
34. [34] Davies, N.M., Kehoe, P.G., Ben-Shlomo, Y., et al. Associations of anti-hypertensive treatments with Alzheimer's disease, vascular dementia, and other dementias. J Alzheimer's Dis 26 (2011), 699–708.
35. [35] Ohrui, T., Tomita, N., Sato-Nakagawa, T., et al. Effects of brain-penetrating ACE inhibitors on Alzheimer disease progression. Neurology 63 (2004), 1324–1325.
36. [36] Gelber, R.P., Ross, G.W., Petrovitch, H., et al. Antihypertensive medication use and risk of cognitive impairment: the Honolulu-Asia Aging Study. Neurology 81 (2013), 888–895.
37. [37] Solfrizzi, V., Scafato, E., Frisardi, V., et al. Angiotensin-converting enzyme inhibitors and incidence of mild cognitive impairment. The Italian Longitudinal Study on Aging. Age 35 (2013), 441–453.
38. [38] Austin, B.P., Nair, V.A., Meier, T.B., et al. Effects of hypoperfusion in Alzheimer's disease. J Alzheimer's Dis 26 (2011), 123–133.
39. [39] Barnes, J.M., Barnes, N.M., Costall, B., et al. Angiotensin II inhibits acetylcholine release from human temporal cortex: implications for cognition. Brain Res 507 (1990), 341–343.
40. [40] Tuppo, E.E., Arias, H.R., The role of inflammation in Alzheimer's disease. Int J Biochem Cell Biol 37 (2005), 289–305.
41. [41] Kehoe, P.G., Miners, S., Love, S., Angiotensins in Alzheimer's disease – friend or foe?. Trends Neurosci 32 (2009), 619–628.
42. [42] Pelisch, N., Hosomi, N., Ueno, M., et al. Blockade of AT1 receptors protects the blood-brain barrier and improves cognition in Dahl salt-sensitive hypertensive rats. Am J Hypertens 24 (2011), 362–368.
43. [43] Danielyan, L., Klein, R., Hanson, L.R., et al. Protective effects of intranasal losartan in the APP/PS1 transgenic mouse model of Alzheimer disease. Rejuvenat Res 13 (2010), 195–201.
44. [44] Takeda, S., Sato, N., Takeuchi, D., et al. Angiotensin receptor blocker prevented beta-amyloid-induced cognitive impairment associated with recovery of neurovascular coupling. Hypertension 54 (2009), 1345–1352.
45. [45] Wang, J., Ho, L., Chen, L., et al. Valsartan lowers brain beta-amyloid protein levels and improves spatial learning in a mouse model of Alzheimer disease. J Clin Investig 117 (2007), 3393–3402.
46. [46] Mogi, M., Li, J.M., Tsukuda, K., et al. Telmisartan prevented cognitive decline partly due to PPAR-gamma activation. Biochem Biophys Res Commun 375 (2008), 446–449.
47. [47] Hanes, D.S., Weir, M.R., Usefulness of ARBs and ACE inhibitors in the prevention of vascular dementia in the elderly. Am J Geriatr Cardiol 16 (2007), 175–182.
48. [48] Barnes, N.M., Cheng, C.H., Costall, B., et al. Angiotensin converting enzyme density is increased in temporal cortex from patients with Alzheimer's disease. Eur J Pharmacol 200 (1991), 289–292.
49. [49] de Oliveira, F.F., Bertolucci, P.H., Chen, E.S., et al. Brain-penetrating angiotensin-converting enzyme inhibitors and cognitive change in patients with dementia due to Alzheimer's disease. J Alzheimer's Dis, 2014.
50. [50] McGuinness, B., Todd, S., Passmore, P., et al. Blood pressure lowering in patients without prior cerebrovascular disease for prevention of cognitive impairment and dementia. Cochrane Database Syst Rev, 2009 CD004034.